Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enbrel Safety in RA Patients with Comorbidities
NCT00132418Phase 4Completed
- Sponsor
- Amgen
- Start
- Apr 2000
- Primary completion
- Feb 2004
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 4, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Enbrel with Placebo (2 arms). Primary endpoint: Incidence of medically important infections at 16 weeks. Started Apr 2000; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00132418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132418.